Matthew Maxwell Donley M.B.A. Net Worth

The estimated Net Worth of Matthew Maxwell Donley is at least $4.7 Million dollars as of 6 March 2024. Mr Donley owns over 40,665 units of Aurinia Pharmaceuticals Inc stock worth over $3,813,990 and over the last 9 years he sold AUPH stock worth over $260,719. In addition, he makes $627,510 as Exec. VP of Operations & Strategy at Aurinia Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr A AUPH stock SEC Form 4 insiders trading

Mr has made over 4 trades of the Aurinia Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 40,665 units of AUPH stock worth $224,064 on 6 March 2024.

The largest trade he's ever made was selling 40,665 units of Aurinia Pharmaceuticals Inc stock on 6 March 2024 worth over $224,064. On average, Mr trades about 3,742 units every 61 days since 2016. As of 6 March 2024 he still owns at least 584,072 units of Aurinia Pharmaceuticals Inc stock.

You can see the complete history of Mr Donley stock trades at the bottom of the page.

Mr. Matthew Maxwell Donley M.B.A. biography

Matthew Maxwell Donley M.B.A. is the Exec. VP of Operations & Strategy at Aurinia Pharmaceuticals Inc.

What is the salary of Mr A?

As the Exec. VP of Operations & Strategy of Aurinia Pharmaceuticals Inc, the total compensation of Mr A at Aurinia Pharmaceuticals Inc is $627,510. There are 6 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.

How old is Mr A?

Mr A is 52, he's been the Exec. VP of Operations & Strategy of Aurinia Pharmaceuticals Inc since . There are 9 older and 6 younger executives at Aurinia Pharmaceuticals Inc. The oldest executive at Aurinia Pharmaceuticals Inc is George Milne, 76, who is the Independent Chairman of the Board.

What's Mr A's mailing address?

Matthew's mailing address filed with the SEC is #140, 14315-118 AVENUE, , EDMONTON, A0, T5L 4S6.

Insiders trading at Aurinia Pharmaceuticals Inc

Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden, and Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.

What does Aurinia Pharmaceuticals Inc do?

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.

Complete history of Mr Donley stock trades at Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc executives and stock owners

Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Peter Greenleaf,
  President, Chief Executive Officer, Director
• Peter S. Greenleaf M.B.A.,
  Pres, CEO & Director
• Maxwell Donley,
  Executive Vice President, Internal Operations & Strategy
• Neil Solomons,
  Chief Marketing Officer
• Massimiliano Colao,
  Chief Commercial Officer
• Robert Huizinga,
  Executive Vice President - Corporate Development
• Matthew Maxwell Donley M.B.A.,
  Exec. VP of Operations & Strategy
• Joseph M. Miller CPA,
  Chief Financial Officer
• Dennis Bourgeault,
  Chief Financial Officer
• Michael Martin,
  Chief Operating Officer
• Daniel Billen,
  Director
• George Milne,
  Independent Chairman of the Board
• Michael Hayden,
  Independent Director
• Stephen P. Robertson,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Joseph Hagan,
  Independent Director
• David Jayne,
  Independent Director
• R. Hector MacKay-Dunn,
  Director
• Jill Leversage,
  Independent Director
• Stephen Robertson,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Timothy Walbert,
  Independent Director
• Max Colao,
  Chief Commercial Officer
• Tim Hermes,
  Vice President of Market Access
• Cara Felish,
  Vice President of Commercial Operations
• Chris Hays,
  Vice President of Marketing
• Fran Lynch,
  Vice President of Sales
• Glenn Schulman,
  Senior Vice President - Corporate Communications and Investor Relations
• Michael R. Martin,
  Chief Bus. Officer
• Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
  Exec. VP of Research
• Scott Michael Habig,
  Chief Commercial Officer
• Volker Knappertz,
  EVP, Research and Development
• Joseph M Miller,
  Chief Financial Officer
• Brinda Balakrishnan,
  Director
• Robert T Foster,
  Director
• Massimilano Colao,
  Chief Commercial Officer
• Jeffrey Allen Bailey,
  Director
• Karen L. Smith,
  Director